Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
Hsieh, Yi-Hsuan
Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients. [electronic resource] - Carcinogenesis Feb 2013 - 475-85 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1460-2180
10.1093/carcin/bgs365 doi
Animals
Apoptosis--drug effects
Blotting, Western
COP9 Signalosome Complex
Carcinoma, Hepatocellular--etiology
Cell Cycle--drug effects
Cell Nucleus--drug effects
Cell Proliferation--drug effects
Cyclin-Dependent Kinase Inhibitor p27--genetics
Cytoplasm--drug effects
Female
Fluorescent Antibody Technique
Hepatitis B Surface Antigens--genetics
Hepatitis B virus--drug effects
Hepatitis B, Chronic--complications
Hepatocytes--cytology
Histone Deacetylase Inhibitors--pharmacology
Humans
Hydroxamic Acids--pharmacology
Immunoenzyme Techniques
Immunoprecipitation
Intracellular Signaling Peptides and Proteins--genetics
Liver Neoplasms--etiology
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Mutant Proteins--genetics
Mutation--genetics
Nuclear Proteins--genetics
Peptide Hydrolases--genetics
Protein Precursors--genetics
RNA, Messenger--genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
TATA Box Binding Protein-Like Proteins--genetics
Two-Hybrid System Techniques
Vorinostat
Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients. [electronic resource] - Carcinogenesis Feb 2013 - 475-85 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1460-2180
10.1093/carcin/bgs365 doi
Animals
Apoptosis--drug effects
Blotting, Western
COP9 Signalosome Complex
Carcinoma, Hepatocellular--etiology
Cell Cycle--drug effects
Cell Nucleus--drug effects
Cell Proliferation--drug effects
Cyclin-Dependent Kinase Inhibitor p27--genetics
Cytoplasm--drug effects
Female
Fluorescent Antibody Technique
Hepatitis B Surface Antigens--genetics
Hepatitis B virus--drug effects
Hepatitis B, Chronic--complications
Hepatocytes--cytology
Histone Deacetylase Inhibitors--pharmacology
Humans
Hydroxamic Acids--pharmacology
Immunoenzyme Techniques
Immunoprecipitation
Intracellular Signaling Peptides and Proteins--genetics
Liver Neoplasms--etiology
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Mutant Proteins--genetics
Mutation--genetics
Nuclear Proteins--genetics
Peptide Hydrolases--genetics
Protein Precursors--genetics
RNA, Messenger--genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
TATA Box Binding Protein-Like Proteins--genetics
Two-Hybrid System Techniques
Vorinostat